Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSB | P07858 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30827957 | 1.00 | CTSL (0.54) | CTSLCTSSCTSBCTSKSMN1; SMN2 | |
| SCHEMBL1876560 | 0.86 | MMP2 (0.52) | SMN1; SMN2ALDH1A1HPGDLMNAHTT | |
| SCHEMBL1876558 | 0.86 | MMP2 (0.52) | SMN1; SMN2ALDH1A1HPGDLMNAHTT | |
| SCHEMBL948159 | 0.83 | ALDH1A1 (0.51) | CTSLCTSSCTSBCTSKSMN1; SMN2 | |
| SCHEMBL7056329 | 0.83 | ALDH1A1 (0.51) | CTSLCTSSCTSBCTSKSMN1; SMN2 | |
| SCHEMBL2685872 | 0.82 | MAOA (0.53) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL11649280 | 0.82 | NPC1 (0.46) | CTSLCTSSCTSBCTSKSMN1; SMN2 | |
| SCHEMBL16089595 | 0.81 | ALDH1A1 (0.50) | CTSLCTSSCTSBCTSKSMN1; SMN2 | |
| SCHEMBL6021199 | 0.81 | CTSL (0.72) | CTSLCTSSCTSBCTSK | |
| SCHEMBL6020267 | 0.81 | CTSL (0.54) | CTSLCTSSCTSBCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118999-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118955477-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118903141-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118903142-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-113227074-B | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118388457-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118290403-A | Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-9833431-B2 | Pharmaceutical combinations for the treatment of cancer | PITNEY PHARMACEUTICALS PTY LIMITED (AU) | 2017-12-05 | — | — | US | disclosed |
| US-9828360-B2 | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160297796-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2014078378-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-6392049-B1 | NITRATION USING NITRIC ACID | AVENTIS PHARMACEUTICALS INC. | 2002-05-21 | — | — | US | disclosed |
| US-6307054-B1 | HEATING A 5-CARBOXY-2,4-DIHYROXYPYRIDINE AND PHOSPHORIC ACID WHERE THE RATIO OF PHOSPHORIC ACID TO WATER IS NOT LESS THAN ABOUT 27 TO 1 WEIGHT %. | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-10-23 | — | — | US | disclosed |
| US-4792565-A | Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds | MITSUI TOATSU CHEMICALS, INC. (JP) | 1988-12-20 | — | — | US | disclosed |
| US-3954756-A | Method for producing pyrimidine | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297796-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, UACA, TYMP | CTSL 2205/4885CTSS 1027/4885CTSB 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.